A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
← catalyst calendarNCT07012395 · readout ≤ 314 d
Sponsored by Spyre Therapeutics, Inc. (industry) · SYRE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
645estimated
Sites
259
Countries
Argentina, Australia, Austria +32
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-27 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ulcerative Colitis
- Inflammatory Bowel Diseases
- Colitis
- Colitis, Ulcerative
Interventions
- Drug: SPY001 — also filed as SPY001-001
- Drug: SPY002 — also filed as SPY002-091
- Drug: SPY003 — also filed as SPY003-207
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Change in Robarts Histopathology Index (RHI)
measured Week 12
Part B: Percentage of participants with clinical remission
measured Week 12
Permalink · SYRE's whole pipeline · Catalyst calendar · Every registered study · What changed